Who
Kaye I. Foster-Cheek
Director
Company insider
Files Form 4 as: Director, Agios Pharmaceuticals; Director, Prime Medicine; SVP, Global Human Resources, Onyx Pharmaceuticals; VP, Human Resources, Johnson & Johnson.
In numbers
- Trades disclosed
- 197
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $16.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 31 Jan 2006
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,510 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,510 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,006 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,006 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
News
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?JNJ · insidermonkey.com · 21 Oct 2026Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?JNJ · aol.com · 21 Oct 2026Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026JNJ · aol.com · 21 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Kaye I. Foster-Cheek; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.